omed industry pharmaceutical drug development founded university of michigan august 2004 ; 12 years ago 2004 08 founders michael clarke max wicha headquarters redwood city california united states key people paul hastings ceo john lewicki r & d chief chuck alaimo operations director revenue us 24 700 000 2012 number of employees 83 2013 47 2007 website www.oncomed.com footnotes references 1 2 3 4 oncomed pharmaceuticals inc. is a public american pharmaceutical company headquartered in redwood city california . 1 the company was founded in august 2004 by two university of michigan investigators michael clarke and max s. wicha . 1 3 as of 2013 update the company had 83 employees . 2 oncomed s drug discovery work focuses on developing targeted antibodies against cancer stem cells . 2 the cancer stem cell technologies on which oncomed depends are licensed from the university of michigan where they were developed by the founders of the company . 3 oncomed went public in 2013 and is listed on nasdaq under the stock symbol omed . 2 3 contents 1 history 1.1 competitors 2 pipeline 3 corporate governance 3.1 paul hastings 4 references history edit in 2007 oncomed consolidated its operations located in mountain view and palo alto california onto the single headquarters campus in redwood city . 1 one of the buildings on the new campus was the former home of next . 1 in 2012 oncomed sponsored the usan nonproprietary name vantictumab for a human igg2 anti frizzled antibody an anti cancer therapeutic . 5 in the same year the company sponsored the usan name demcizumab for a human igg2 anti dll4 antibody also an anti cancer therapeutic . 6 in 2014 oncomed entered into an anti cancer stem cell therapeutic development agreement with celgene encompassing demcizumab and five other biologics from oncomed s pipeline . 7 8 as of 2013 update co founder max wicha was the director of the university of michigan comprehensive cancer center and remained a consultant to oncomed while co founder michael clarke had taken up a position at stanford university . 3 competitors edit in 2013 oncomed had at least two direct competitors both public american companies stemline therapeutics and verastem . 2 by 2014 the list of firms pursuing therapies targeting cancer stem cells had grown to include boston biomedical a subsidiary of dainippon sumitomo pharma glaxosmithkline astellas pharma sanofi the american subsidiary and pfizer ; however stemline and verastem remain the only two competitors solely focused on cancer stem cells . 7 one analyst holds that oncomed is the best positioned of the three companies focused on the cancer stem cell area . 7 pipeline edit clinical pipeline oct 2014 7 name id clinical phase demcizumab ib ii tarextumab ib ii anti notch 2 3 omp 59r5 9 ib ii vantictumab omp 18r5 4 ib ipafricept omp 54f28 10 ib anti notch1 i as of october 2014 update oncomed had five clinical stage drugs in development and two discovery stage investigations ; no oncomed therapies have made it to market yet . 7 two candidate drugs being co developed with bayer ipafricept and vantictumab showed in mid 2014 indications of causing mild to moderate bone related side effects among phase i clinical trial participants an observation which led the company to halt enrollment and dosing in the trials and which contributed to a sharp decline in share price . 7 10 11 corporate governance edit as of 2013 update oncomed s chief executive officer ceo was paul hastings 2 who took the post in 2006 . 12 as of 2007 update the company s head of r & d was john lewicki and the director of operations was chuck alaimo . 1 paul hastings edit while serving as oncomed s ceo hastings was also a member of the board of directors for the california healthcare institute and the bay area biosciences association as well as chairing the board of the biotechnology industry organization . 12 hastings education includes a bachelor s degree in pharmacy from the university of rhode island . 12 references edit a b c d e f leuty ron 28 oct 2007 . the next big thing oncomed finds a home . san francisco business times . a b c d e f timmerman luke 18 jun 2013 . oncomed pharmaceuticals soars in ipo debut . xconomy . united states . a b c d e u m start up oncomed has initial public offering press release . university of michigan health system . 22 jul 2013 . a b leuty ron 5 jul 2013 . oncomed targets 4 million shares in ipo . san francisco business times . statement on a nonproprietary name adopted by the usan council pdf . ama . 28 nov 2012 . n12 155 . registration required statement on a nonproprietary name adopted by the usan council pdf . ama . n12 07 . retrieved 1 dec 2014 . registration required a b c d e f de kanak kanti 14 oct 2014 . is it time to consider oncomed pharmaceuticals again . seeking alpha . staff january 1 2014 . oncomed celgene in 3.3 b cancer stem cell collaboration . industry watch . gen. eng . biotechnol . news . p. 8 . oncomed pharmaceuticals initiates phase 1b 2 clinical trial of anti cancer stem cell therapeutic omp 59r5 anti notch2 3 in small cell lung cancer sclc and amends phase1b 2 pancreatic cancer trial pdf press release . oncomed . 14 may 2013 . a b grover natalie 13 jun 2014 . oncomed halts enrollment in trials of two cancer drugs . reuters . calia michael 13 jun 2014 . fda imposes partial hold on oncomed early stage cancer drug trial . the wall street journal . a b c paul j. hastings . leadership . california healthcare institute . archived from the original on 2 oct 2011 . retrieved from https en.wikipedia.org w index.php title oncomed & oldid 720958900 categories 2004 establishments in californiapharmaceutical companies established in 2004american companies established in 2004hidden categories pages with login required references or sourcesarticles containing potentially dated statements from 2013all articles containing potentially dated statementsarticles containing potentially dated statements from october 2014articles containing potentially dated statements from 2007 navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 18 may 2016 at 23 25 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view